Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$7.4MCash on Hand
6.6mo Cash Runway
Follow LTRN by emailGet an email when LTRN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LTRN, unsubscribe in one click. Privacy
📣 What LTRN Says Is Next
second half of 2026 · “Additional clinical data updates from the HARMONIC™ trial are expected in the second half of 2026.”
Company press release, May 15, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Oct 19, 2026 ·
Shareholder vote Lantern Pharma's 2026 annual meeting is set for December 1, 2026, virtually. Shareholders will vote on six directors, raising authorized common stock to 50 million shares, adding 250,000 shares to the equity plan, and issuing up to 3,669,725 shares on warrants sold to an institutional investor. Form DEF 14A · SEC filing
Oct 1, 2026 ·
Listing Nasdaq notified Lantern Pharma that its common stock is below the $35,000,000 minimum market value of listed securities for 30 consecutive business days, and it also fails Listing Rules 5550(b)(1) and 5550(b)(3). The company has until March 24, 2027 to regain compliance. Form 8-K · SEC filing
Sep 30, 2026 ·
Financing Lantern Pharma is offering 1,469,725 shares of common stock at $1.09 per share, plus pre-funded warrants for 2,200,000 shares, with concurrent private placement warrants for up to 3,669,725 shares exercisable at $1.09 upon shareholder approval. Form 424B5 · SEC filing
Sep 30, 2026 ·
Financing Lantern Pharma agreed to sell 1,469,725 common shares at $1.09 each in a registered direct offering, plus pre-funded warrants for up to 2,200,000 shares at $1.0899, closing September 30, 2026. A concurrent private placement issued warrants for up to 3,669,725 shares at $1.09, subject to stockholder approval. Form 8-K · SEC filing · Press release
Sep 24, 2026 ·
Lantern Pharma hosted a September 23, 2026 webinar on its Open-Medicine AI multi-agentic platform for drug development. A replay is available online, and the presentation is furnished as Exhibit 99.1. Form 8-K · SEC filing · Press release
Sep 23, 2026 ·
Lantern Pharma will host a live webinar today at 12:30 PM Eastern to present the growth plan for its Open-Medicine AI platform, including market, roadmap, economics and partnership discussions. The event includes a live demonstration and Q&A. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 14, 2026 ·
Earnings Reported Q2 2026 results: cash and marketable securities of about $7.4 million as of June 30, 2026, after about $4.4 million in gross proceeds from a May 14, 2026 registered direct offering. Loss from operations fell about 25% year over year to about $3.5 million. Open Medicine AI was set up as a separate company. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 2 · Recruiting · A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma Registry primary completion date, not a results date
Nov 2028 · Phase 1 · Recruiting · Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors Registry primary completion date, not a results date
📊 Drug Pipeline
Drug
Indication
Most advanced trial
Status
Irofulven
Metastatic Castration-Resistant Prostate Cancer Patients
Also used in these trials (approved or third-party drugs, not LTRN's own candidates): Dimesna (BNP7787), Cisplatin, Carboplatin, Olaparib, Pemetrexed Disodium.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
LTRN holds $7.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.4M/quarter from operations,
an estimated runway of 6.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:67 · High
Cash runway 7 months +30
ATM program on file since Jul 2025 +15
Shelf registration (S-3, May 2024) +10
Going-concern doubt in the latest 10-Q +15For this reason, there is substantial doubt about the Company’s ability to continue as a going concern in the absence of obtaining substantial additional funding.10-Q, Aug 2026
Share count +18% in a year +7
Raised after last reported balance sheet (Sep 2026) -10
Share count 12,784,146 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full LTRN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LTRN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.